Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?
Lloyd AJ, Nafees B, Ziani E, Nicolas L, Fordham BA, Soubeyrand B, Bornhöft C. Lloyd AJ, et al. Among authors: soubeyrand b. Patient Prefer Adherence. 2015 Oct 27;9:1517-24. doi: 10.2147/PPA.S87229. eCollection 2015. Patient Prefer Adherence. 2015. PMID: 26604704 Free PMC article. Review.
Corrigendum to "Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines" [Vaccine 34 (2016) 757-761].
Van Damme P, Bonanni P, Bosch FX, Joura E, Kjaer SK, Meijer CJLM, Petry KU, Soubeyrand B, Verstraeten T, Stanley M. Van Damme P, et al. Among authors: soubeyrand b. Vaccine. 2016 Sep 7;34(39):4759-4760. doi: 10.1016/j.vaccine.2016.07.035. Epub 2016 Jul 25. Vaccine. 2016. PMID: 27461456 Free article. No abstract available.
Safety and immune response to a challenge dose of hepatitis B vaccine in healthy children primed 10years earlier with hexavalent vaccines in a 3, 5, 11-month schedule: An open-label, controlled, multicentre trial in Italy.
Zanetti A, Desole MG, Romanò L, d'Alessandro A, Conversano M, Ferrera G, Panico MG, Tomasi A, Zoppi G, Zuliani M, Thomas S, Soubeyrand B, Eymin C, Lockhart S. Zanetti A, et al. Among authors: soubeyrand b. Vaccine. 2017 Jul 13;35(32):4034-4040. doi: 10.1016/j.vaccine.2017.05.047. Epub 2017 Jun 16. Vaccine. 2017. PMID: 28624307 Clinical Trial.
Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, Van Damme P, Bosch X. Petry KU, et al. Among authors: soubeyrand b. Hum Vaccin Immunother. 2018 Jul 3;14(7):1800-1806. doi: 10.1080/21645515.2018.1450125. Epub 2018 May 24. Hum Vaccin Immunother. 2018. PMID: 29553886 Free PMC article.
Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Zimmermann U, et al. Among authors: soubeyrand b. Vaccine. 2013 Mar 1;31(11):1496-502. doi: 10.1016/j.vaccine.2012.12.081. Epub 2013 Jan 10. Vaccine. 2013. PMID: 23313654 Clinical Trial.
Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster.
Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B; Pentavac Study Group. Mallet E, et al. Among authors: soubeyrand b. Vaccine. 2004 Mar 29;22(11-12):1415-22. doi: 10.1016/j.vaccine.2003.10.025. Vaccine. 2004. PMID: 15063564 Clinical Trial.
Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age.
Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B; Pentavac study group. Langue J, et al. Among authors: soubeyrand b. Vaccine. 2004 Mar 29;22(11-12):1406-14. doi: 10.1016/j.vaccine.2003.10.026. Vaccine. 2004. PMID: 15063563 Clinical Trial.
56 results